Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Rectal Neoplasms 1Rare Diseases 1Oligodendroglioma 1Insulinoma 1Glucagonoma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Temozolomide 162Radiosurgery 114Radiotherapy 99Bevacizumab 95Magnetic Resonance Spectroscopy 64Carboplatin 48Etoposide 34Surgical Procedures, Operative 33Irinotecan 33pembrolizumab 32Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 29Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Streptozocin × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡